MétaCan
Menu
Back to cohort
Record W4410585961 · doi:10.1136/bmjmed-2024-001126

Metformin for covid-19: systematic review and meta-analysis of randomised controlled trials

2025· article· en· W4410585961 on OpenAlexafffund
Saifur Rahman Chowdhury, Nazmul Islam, Qi Zhou, Md. Kamrul Hasan, Mahmudur Rahman Chowdhury, Reed Siemieniuk, Arnav Agarwal, Romina Brignardello‐Petersen, Thomas Agoritsas, Per Olav Vandvik, Dena Zeraatkar, Gordon Guyatt

Bibliographic record

VenueBMJ Medicine · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicMetabolism, Diabetes, and Cancer
Canadian institutionsMcMaster UniversityImpact
FundersMedical Research CouncilCanadian Institutes of Health ResearchEinstein Stiftung Berlin
KeywordsMedicineMeta-analysisMetforminConfidence intervalRelative riskRandomized controlled trialSystematic reviewMEDLINEGuidelinePlaceboAbsolute risk reductionInternal medicineIntensive care medicineAlternative medicinePathology

Abstract

fetched live from OpenAlex

Objective: To summarise the effects of metformin on covid-19 to inform a World Health Organization (WHO) clinical practice guideline. Design: Systematic review and meta-analysis. Data sources: As part of a living systematic review and network meta-analysis of drug treatments for covid-19 (covid-19 LNMA), a search was performed of the WHO covid-19 database, six Chinese databases, and the Epistemonikos Foundation's Living Overview of the Evidence covid-19 Repository (covid-19 L-OVE). Eligibility criteria for selecting studies: Randomised controlled trials that compared metformin with placebo in patients with acute covid-19 infection. Data synthesis: Frequentist pairwise meta-analyses were performed using the restricted maximum likelihood random effects model. The effects of interventions on selected outcomes were summarised using risk ratios, risk difference, and mean difference when appropriate, along with their corresponding 95% confidence intervals (CIs). To estimate absolute effects, the control arm event rate was used as the baseline risk. The risk of bias of the included studies was assessed using a modification of the Cochrane risk of bias 2.0 tool and the certainty of evidence using the GRADE (grading of recommendations assessment, development and evaluation) approach, with the minimally important difference in effect as the threshold. Results: Three randomised controlled trials of 1869 patients were included; one study provided long term follow-up on long covid. Metformin might have little or no impact on mortality (risk ratio 0.76, 95% CI 0.30 to 1.90; risk difference 3 fewer per 1000, 95% CI 8 fewer to 11 more; low certainty). The effects of metformin on admission to hospital because of covid-19 remain uncertain (risk ratio 0.74, 95% CI 0.28 to 1.95; risk difference 15 fewer per 1000, 95% CI 42 fewer to 55 more; very low certainty). Metformin results in little or no difference in adverse effects leading to discontinuation (risk difference 0.2 more per 1000, 95% CI 2.7 fewer to 3.1 more; high certainty). Metformin might decrease the development of long covid (risk ratio 0.6, 95% CI 0.4 to 0.9; risk difference 41 fewer per 1000, 95% CI 62 fewer to 10 fewer; low certainty). However, the effect is based on a single trial of 1126 patients, which has a high risk of bias owing to missing data, and nearly half of the participants were unvaccinated. Conclusions: Current evidence based on randomised trials suggests no significant effect of metformin on acute clinical outcomes in patients with non-severe covid-19. Metformin might reduce the incidence of long covid when used to treat patients with non-severe acute covid-19 infection, but this was suggested by low certainty evidence from a single trial.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.042
metaresearch head score (Gemma)0.103
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.042
Threshold uncertainty score0.220

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0420.103
Meta-epidemiology (narrow)0.0040.002
Meta-epidemiology (broad)0.0260.038
Bibliometrics0.0130.010
Science and technology studies0.0010.001
Scholarly communication0.0040.003
Open science0.0030.002
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.0070.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.094
GPT teacher head0.437
Teacher spread0.343 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueBMJ MedicineSame topicMetabolism, Diabetes, and CancerFrench-language works237,207